Skip to main content
SpringerLink
Log in

Stoffwechsel, Knochen, Herz-Kreislauf — was bei AIDS-Patienten anders ist

Gesundheitsvorsorge bei HIV-Infizierten

Treatment of HIV-infected patients: metabolism, bone, cardiovascular — what is part of routine care?

  • FORTBILDUNG . ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Zusammenfassung

In der Therapie HIV-Infizierter müssen neben den Folgen der Immunsuppression Risiken wie Rauchen, Drogenkonsum und sexuell übertragbare Erkrankungen beachtet werden. Hinzu kommen Nebenwirkungen der antiretroviralen Medikation und zunehmend typische altersassoziierte Risiken. Dieser Beitrag fokussiert auf Maßnahmen, die zusätzlich zur Therapie und zum Monitoring der HIV-Infektion erforderlich sind.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Jallow A, Ljunggren G, Wandell P, Carlsson AC. Prevalence, incidence, mortality and co-morbidities amongst human immunodeficiency virus (HIV) patients in Stockholm County, Sweden — the Greater Stockholm HIV Cohort Study. AIDS Care. 2015;27:142–9

    Article  PubMed  Google Scholar 

  2. Rasmussen LD, May MT, Kronborg G, Larsen CS, Pedersen C, Gerstoft J et al. Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study. Lancet HIV. 2015;2:e288–98

    Article  PubMed  Google Scholar 

  3. Schouten J, Wit FW, Stolte IG, Kootstra NA, van d, V, Geerlings SE et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59:1787–97

    Article  PubMed  Google Scholar 

  4. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120–6

    Article  PubMed  Google Scholar 

  5. Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366(9483):378–84

    Article  CAS  PubMed  Google Scholar 

  6. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373:795–807

    Article  CAS  PubMed  Google Scholar 

  7. Lange CG, Lederman MM, Medvik K, Asaad R, Wild M, Kalayjian R et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS. 2003;17:2015–23

    Article  PubMed  Google Scholar 

  8. Kim HN, Harrington RD, Crane HM, Dhanireddy S, Dellit TH, Spach DH. Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS. 2009;20:595–600

    Article  CAS  PubMed  Google Scholar 

  9. Heuft MM, Houba SM, van den Berk GE, Smissaert vdH, van Dam AP, Dijksman LM et al. Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection. AIDS. 2014;24;28(7):999–1005

    Article  CAS  PubMed  Google Scholar 

  10. Cheng A, Chang SY, Sun HY, Tsai MS, Liu WC, Su YC et al. Long-term durability of responses to 2 or 3 doses of hepatitis A vaccination in HIV-positive adults on antiretroviral therapy. J Infect Dis. 2017;215:606–13

    PubMed  Google Scholar 

  11. Cianflone NF, Wallace MR. Stimulating Evidence for Pneumococcal Conjugate Vaccination Among HIV-Infected Adults. J Infect Dis. 2015;212:1–4

    Article  Google Scholar 

  12. Zaaqoq AM, Khasawneh FA, Smalligan RD. Cardiovascular Complications of HIV-Associated Immune Dysfunction. Cardiol Res Pract. 2015;2015:302638.

    Google Scholar 

  13. Erlandson KM, O’Riordan M, Labbato D, McComsey GA. Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;65:290–8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Gazzola L, Bellistri GM, Tincati C, Ierardi V, Savoldi A, Del SA et al. Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients. J Transl Med. 2013;11:51

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Jansen K, Thamm M, Bock CT, Scheufele R, Kucherer C, Muenstermann D et al. High Prevalence and High Incidence of Coinfection with Hepatitis B, Hepatitis C, and Syphilis and Low Rate of Effective Vaccination against Hepatitis B in HIV-Positive Men Who Have Sex with Men with Known Date of HIV Seroconversion in Germany. PLoS ONE 2015;10(11):e0142515

    Article  PubMed  PubMed Central  Google Scholar 

  16. Klein MB, Rockstroh JK, Wittkop L. Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. Curr Opin HIV AIDS 2016;11(5):521–6

    Article  CAS  PubMed  Google Scholar 

  17. Heuft MM, Houba SM, van den Berk GE, Smissaert vdH, van Dam AP, Dijksman LM et al. Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection. AIDS. 2014;28:999–1005

    Article  CAS  PubMed  Google Scholar 

  18. Brejt N, Gilleece Y, Fisher M. Acute hepatitis C: changing epidemiology and association with HIV infection. J HIV Ther. 2007;12:3–6

    PubMed  Google Scholar 

  19. Ghosn J, Pierre-Francois S, Thibault V, Duvivier C, Tubiana R, Simon A et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med. 2004;5:303–6

    Article  CAS  PubMed  Google Scholar 

  20. van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS. 2010;24:1799–812

    Article  PubMed  Google Scholar 

  21. Vogel M, Deterding K, Wiegand J, Gruner NH, Baumgarten A, Jung MC et al. Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection. Clin Infect Dis. 2009;49:317–9

    Article  PubMed  Google Scholar 

  22. El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016;64:130–7

    Article  CAS  PubMed  Google Scholar 

  23. Franceschi S, Jaffe H. Cervical cancer screening of women living with HIV infection: a must in the era of antiretroviral therapy. Clin Infect Dis. 2007;45:510–3

    Article  PubMed  Google Scholar 

  24. Yinnon AM, Coury-Doniger P, Polito R, Reichman RC. Serologic response to treatment of syphilis in patients with HIV infection. Arch Intern Med. 1996;156:321–5

    Article  CAS  PubMed  Google Scholar 

  25. Kotsafti O, Paparizos V, Kourkounti S, Chatziioannou A, Nicolaidou E, Kapsimali V et al. Early syphilis affects markers of HIV infection. Int J STD AIDS. 2016;27:739–45

    Article  CAS  PubMed  Google Scholar 

  26. Palacios R, Jimenez-Onate F, Aguilar M, Galindo MJ, Rivas P, Ocampo A et al. Impact of syphilis infection on HIV viral load and CD4 cell counts in HIV-infected patients. J Acquir Immune Defic Syndr. 2007;44:356–9

    Article  PubMed  Google Scholar 

  27. Mdodo R, Frazier EL, Dube SR, Mattson CL, Sutton MY, Brooks JT et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med 2015;162:335–44

    Article  PubMed  Google Scholar 

  28. Elliot ER, Singh S, Tyebally S, Gedela K, Nelson M. Recreational drug use and chemsex among HIV-infected in-patients: a unique screening opportunity. HIV Med. 2017; doi: 10.1111/hiv.12487. [Epub ahead of print]

  29. Feuillet P, Lert F, Tron L, Aubriere C, Spire B, Dray-Spira R. Prevalence of and factors associated with depression among people living with HIV in France. HIV Med. 2016; doi: 10.1111/hiv.12438. [Epub ahead of print]

  30. Carrieri MP, Marcellin F, Fressard L, Preau M, Sagaon-Teyssier L, Suzan-Monti M et al. Suicide risk in a representative sample of people receiving HIV care: Time to target most-at-risk populations (ANRS VESPA2 French national survey). PLoS ONE. 2017;12(2):e0171645

    Article  PubMed  PubMed Central  Google Scholar 

  31. Mollan KR, Smurzynski M, Eron JJ, Daar ES, Campbell TB, Sax PE et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014;161:1–10

    Article  PubMed  PubMed Central  Google Scholar 

  32. Gomes A, Reyes EV, Garduno LS, Rojas R, Mir MG, Del RE et al. Incidence of Diabetes Mellitus and Obesity and the Overlap of Comorbidities in HIV+ Hispanics Initiating Antiretroviral Therapy. PLoS ONE. 2016;11:e0160797

    Article  PubMed  PubMed Central  Google Scholar 

  33. Feingold KR, Grunfeld C. The Effect of Inflammation and Infection on Lipids and Lipoproteins. [Updated 2015 Jun 12]. In: De Groot LJ, Chrousos G, Dungan K et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK326741

  34. Gomes AR, Souteiro P, Silva CG, Sousa-Pinto B, Almeida F, Sarmento A et al. Prevalence of testosterone deficiency in HIV-infected men under antiretroviral therapy. BMC Infect Dis. 2016;16:628

    Article  PubMed  PubMed Central  Google Scholar 

  35. Martin-Iguacel R, Negredo E, Peck R, Friis-Moller N. Hypertension Is a Key Feature of the Metabolic Syndrome in Subjects Aging with HIV. Curr Hypertens Rep. 2016;18:46

    Article  PubMed  Google Scholar 

  36. van Zoest RA et al. Higher Prevalence of Hypertension in HIV-1-Infected Patients on Combination Antiretroviral Therapy Is Associated With Changes in Body Composition and Prior Stavudine Exposure. Clin Infect Dis. 2016;63:205–13

    Article  PubMed  Google Scholar 

  37. Gravemann S, Brinkkoetter PT, Vehreschild JJ, Franke B, Ehren K, Bunemann E et al. Low-grade proteinuria is highly prevalent in HIV-positive patients on antiretroviral treatment. AIDS. 2014;28:1783–9

    Article  CAS  PubMed  Google Scholar 

  38. Ibrahim F, Naftalin C, Cheserem E, Roe J, Campbell LJ, Bansi L et al. Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. AIDS. 2010;24:2239–44

    Article  CAS  PubMed  Google Scholar 

  39. Roe J, Campbell LJ, Ibrahim F, Hendry BM, Post FA. HIV care and the incidence of acute renal failure. Clin Infect Dis. 2008;47:242–9

    Article  PubMed  Google Scholar 

  40. Franceschini N, Napravnik S, Finn WF, Sczech LA, Eron JJ, Jr. Immunosuppression, hepatitis C infection, and acute renal failure in HIV-infected patients. J Acquir Immune Defic Syndr. 2006;42:368–72

    Article  CAS  PubMed  Google Scholar 

  41. Franceschini N, Napravnik S, Eron JJ, Jr., Szczech LA, Finn WF. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int. 2005;67:1526–31

    Article  PubMed  Google Scholar 

  42. Alvarez E, Belloso WH, Boyd MA, Inkaya AC, Hsieh E, Kambugu A et al. Which HIV patients should be screened for osteoporosis: an international perspective. Curr Opin HIV AIDS. 2016;11:268–76

    Article  PubMed  Google Scholar 

  43. D’Abramo A, Zingaropoli MA, Oliva A, D’Agostino C, Al MS, De LG et al. Higher Levels of Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and Endovascular Damage in HIV-Suppressed Patients. PLoS ONE. 2016;11:e0149601

    Article  PubMed  PubMed Central  Google Scholar 

  44. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506–12

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Bhagwat P, Ofotokun I, McComsey GA, Brown T, Moser C, Sugar CA et al. Predictors of Severe Weight/Body Mass Index Gain Following Antiretroviral Initiation. Conference on Retroviruses and Opportunistic Infections, February 13–16, 2017, Seattle, Washington, Abstract No. 695

  46. Non LR, Escota GV, Powderly WG. HIV and its relationship to insulin resistance and lipid abnormalities. Transl Res. 2017;183:41–56

    Article  CAS  PubMed  Google Scholar 

  47. Macias J, Pineda JA, Real LM. Non-Alcoholic Fatty Liver Disease in HIV Infection. AIDS Rev. 2017;19:35–46

    PubMed  Google Scholar 

  48. Morse CG, McLaughlin M, Matthews L, Proschan M, Thomas F, Gharib AM et al. Nonalcoholic Steatohepatitis and Hepatic Fibrosis in HIV-1-Monoinfected Adults With Elevated Aminotransferase Levels on Antiretroviral Therapy. Clin Infect Dis. 2015;60:1569–78

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Rivero-Juarez A, Camacho A, Merchante N, Perez-Camacho I, Macias J, Ortiz-Garcia C et al. Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. PLoS ONE. 2013;8:e68953

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Sterling RK, Smith PG, Brunt EM. Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. J Clin Gastroenterol. 2013;47:182–7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Guaraldi G, Lonardo A, Ballestri S, Zona S, Stentarelli C, Orlando G et al. Human immunodeficiency virus is the major determinant of steatosis and hepatitis C virus of insulin resistance in virus-associated fatty liver disease. Arch Med Res. 2011;42:690–7

    Article  CAS  PubMed  Google Scholar 

  52. Ofotokun I, Titanji K, Vunnava A, Roser-Page S, Vikulina T, Villinger F et al. Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection. AIDS. 2016;30:405–14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T et al. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. J Infect Dis. 2015;212:1241–9

    Article  PubMed  PubMed Central  Google Scholar 

  54. Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR, Domingo P et al. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther. 2013;18:905–13

    Article  CAS  PubMed  Google Scholar 

  55. Haverkort ME, van der Spek BW, Lips P, Slieker WA, ter HR, Huitema AD et al. Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literature. Scand J Infect Dis. 2011;43:821–6

    Article  CAS  PubMed  Google Scholar 

  56. Calmy A, Fux CA, Norris R, Vallier N, Delhumeau C, Samaras K et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis. 2009;200:1746–54

    Article  CAS  PubMed  Google Scholar 

  57. Borges AH, Hoy J, Florence E, Sedlacek D, Stellbrink HJ, Uzdaviniene V et al. Antiretrovirals, fractures and osteonecrosis in a large international HIV cohort. Clin Infect Dis. 2017;64:1413–21

    Article  PubMed  Google Scholar 

  58. Wyatt CM. Antiretroviral therapy and the kidney. Top Antivir Med 2014;22:655–8

    PubMed  Google Scholar 

  59. Moriyama Y, Minamidate Y, Yasuda M, Ehara H, Kikuchi M, Tsuchiya T et al. Acute renal failure due to bilateral ureteral stone impaction in an HIV-positive patient. Urol Res. 2008;36:275–7

    Article  PubMed  Google Scholar 

  60. Nishijima T, Hamada Y, Watanabe K, Komatsu H, Kinai E, Tsukada K et al. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients. PLoS ONE. 2013;8:e77268

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Tattevin P, Revest M, Chapplain JM, Ratajczak-Enselme M, Arvieux C, Michelet C. Increased risk of renal stones in patients treated with atazanavir. Clin Infect Dis. 2013;56:1186

    Article  PubMed  Google Scholar 

  62. Hamada Y, Nishijima T, Watanabe K, Komatsu H, Tsukada K, Teruya K et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis. 2012;55:1262–9

    Article  CAS  PubMed  Google Scholar 

  63. Rockwood N, Mandalia S, Bower M, Gazzard B, Nelson M. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS. 2011;25:1671–3

    Article  CAS  PubMed  Google Scholar 

  64. Iwata K, Nagata M, Watanabe S, Nishi S. Distal renal tubular acidosis without renal impairment after use of tenofovir: a case report. BMC Pharmacol Toxicol. 2016;17:52

    Article  PubMed  PubMed Central  Google Scholar 

  65. Bhogal S. Tenofovir-Induced Fanconi Syndrome Presenting as Hypokalemic Periodic Paralysis. Am J Ther. 2016 [Epub ahead of print]

  66. Lify B, Dabo G, Nascimento O, Iraqui S, Elkhayat S, Zamd M et al. Fanconi syndrome induced by tenofovir: A case report. Saudi J Kidney Dis Transpl. 2016;27:808–11

    Article  PubMed  Google Scholar 

  67. Mitra S, Priscilla R, Rajeev K, Sauradeep S, Rajkumar S, Cherian AO. Renal tubular dysfunction associated with tenofovir therapy. J Assoc Physicians India. 2014;62:580–2

    PubMed  Google Scholar 

  68. Gupta SK, Anderson AM, Ebrahimi R, Fralich T, Graham H, Scharen-Guivel V et al. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients. PLoS ONE. 2014;9:e92717

    Article  PubMed  PubMed Central  Google Scholar 

  69. Gutierrez F, Fulladosa X, Barril G, Domingo P. Renal tubular transporter-mediated interactions of HIV drugs: implications for patient management. AIDS Rev. 2014;16:199–212

    PubMed  Google Scholar 

  70. Maggi P, Montinaro V, Rusconi S, Di BA, Bellagamba R, Bonfanti P et al. The problem of renal function monitoring in patients treated with the novel antiretroviral drugs. HIV Clin Trials. 2014;15:87–91

    Article  CAS  PubMed  Google Scholar 

  71. Brothers CH, Hernandez JE, Cutrell AG, Curtis L, it-Khaled M, Bowlin SJ et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr. 2009;51:20–8

    Article  CAS  PubMed  Google Scholar 

  72. Costagliola D, Lang S, Mary-Krause M, Boccara F. Abacavir and cardiovascular risk: reviewing the evidence. Curr HIV/AIDS Rep. 2010;7:127–33

    Article  PubMed  Google Scholar 

  73. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318–30

    Article  CAS  PubMed  Google Scholar 

  74. Lewis JM, Stott KE, Monnery D, Seden K, Beeching NJ, Chaponda M et al. Managing potential drug-drug interactions between gastric acid-reducing agents and antiretroviral therapy: experience from a large HIV-positive cohort. Int J STD AIDS. 2016;27:105–9

    Article  CAS  PubMed  Google Scholar 

  75. Tseng A, Foisy M. Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs. Curr Infect Dis Rep. 2012;14:67–82

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infektionsmedizinisches Centrum Hamburg (ICH), Grindelallee 35, D-20146, Hamburg, Deutschland

    Hans-Jürgen Stellbrink

Authors
  1. Hans-Jürgen Stellbrink
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans-Jürgen Stellbrink.

Additional information

INTERESSENKONFLIKT

Der Autor erklärt, dass er sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließ. Er legt folgende potenziellen Interessenkonflikte offen: Durchführung von Studien für AbbVie, Gilead, Janssen-Cilag, ViiV, GSK und MSD; Beratungs- und Vortragstätigkeit für AbbVie, Gilead, Janssen-Cilag, MSD, Teva und BMS.Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

This article is part of a supplement not sponsored by the industry.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stellbrink, HJ. Gesundheitsvorsorge bei HIV-Infizierten. MMW - Fortschritte der Medizin 159 (Suppl 2), 14–23 (2017). https://doi.org/10.1007/s15006-017-9047-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-017-9047-1

Keywords

Search

Navigation